Advertisement
Screener

ORAMED PHARMACEUTICALS INC. (ORMP) Income (Loss) from Continuing Operations before Income Taxes, Domestic

1.9 / 5 stars · 28/74 Roast Me

ORAMED PHARMACEUTICALS INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic

ORAMED PHARMACEUTICALS INC. (ORMP) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$8.85 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.

Financial Statements › Income Statement › Pre-tax Income

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2025-03-27

  • ORAMED PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$8.85M, a 176.29% decline from fiscal 2023.
  • ORAMED PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was $11.60M.
  • ORAMED PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$11.16M.
  • ORAMED PHARMACEUTICALS INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2021 was $5.31M, a 85.04% increase from fiscal 2020.
Period endIncome (Loss) from Continuing Operations before Income Taxes, Domestic 4 monthIncome (Loss) from Continuing Operations before Income Taxes, Domestic 12 monthIncome (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filedIncome (Loss) from Continuing Operations before Income Taxes, Domestic 125 monthIncome (Loss) from Continuing Operations before Income Taxes, Domestic 137 month
2024-12-31-$8.85M
10-K · filed 2025-03-27
2023-12-31$11.60M
10-K · filed 2025-03-27
2022-12-31-$11.16M
10-K · filed 2024-03-06
$11.16M
10-K · filed 2023-03-06
2021-12-31$3.64M
10-K · filed 2023-03-06
2021-08-31$5.31M
10-K · filed 2023-03-06
2020-08-31$2.87M
10-K · filed 2021-11-24
2019-08-31$2.28M
10-K · filed 2020-11-24
2018-08-31$1.93M
10-K · filed 2019-11-27
2017-08-31$1.11M
10-K · filed 2019-11-27
2016-08-31$959.00K
10-K · filed 2018-11-28
2015-08-31$1.23M
10-K · filed 2017-11-29
2014-08-31$893.00K
10-K · filed 2016-11-25
-$893.00K
10-K · filed 2014-11-14
2013-08-31$1.19M
10-K · filed 2015-11-25
-$1.19M
10-K · filed 2013-11-27
-$9.63M
10-K · filed 2013-11-27
2012-08-31-$599.00K
10-K · filed 2014-11-14
-$599.07K
10-K · filed 2012-12-12
-$8.44M
10-K · filed 2012-12-12
2011-08-31-$415.84K
10-K · filed 2012-12-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Zentalis Pharmaceuticals, Inc. (ZNTL)United States$0.196B-2.48
Nkarta, Inc. (NKTX)United States$0.205B-1.73
Fortress Biotech, Inc. (FBIO)United States$0.188B0.91
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
PepGen Inc. (PEPG)United States$0.186B-1.73
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
Foghorn Therapeutics Inc. (FHTX)United States$0.213B-4.43
Organogenesis Holdings Inc. (ORGO)United States$0.182B-3.70
Eledon Pharmaceuticals, Inc. (ELDN)United States$0.219B-3.23
Whitehawk Therapeutics, Inc. (WHWK)United States$0.221B